A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis.
Saved in:
| Title: | A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis. |
|---|---|
| Authors: | Spelman L; Veracity Clinical Research, Brisbane, Australia., Rubel D; Woden Dermatology, ACT, Australia., Brnabic A; Eli Lilly Australia Pty Limited, West Ryde, Australia., Burkhardt N; Eli Lilly Australia Pty Limited, West Ryde, Australia., Riedl E; Eli Lilly Ges.m.b.H, Vienna, Austria.; Department of Dermatology, Medical University of Vienna, Vienna, Austria., Foley P; Skin Health Institute, Carlton, Australia.; The University of Melbourne, St Vincent's Hospital Melbourne, Fitzroy, Australia. |
| Source: | The Journal of dermatological treatment [J Dermatolog Treat] 2022 Feb; Vol. 33 (1), pp. 329-335. Date of Electronic Publication: 2020 Apr 21. |
| Publication Type: | Clinical Trial, Phase III; Journal Article |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 32314628 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Spelman+L%22">Spelman L</searchLink>; Veracity Clinical Research, Brisbane, Australia.<br /><searchLink fieldCode="AU" term="%22Rubel+D%22">Rubel D</searchLink>; Woden Dermatology, ACT, Australia.<br /><searchLink fieldCode="AU" term="%22Brnabic+A%22">Brnabic A</searchLink>; Eli Lilly Australia Pty Limited, West Ryde, Australia.<br /><searchLink fieldCode="AU" term="%22Burkhardt+N%22">Burkhardt N</searchLink>; Eli Lilly Australia Pty Limited, West Ryde, Australia.<br /><searchLink fieldCode="AU" term="%22Riedl+E%22">Riedl E</searchLink>; Eli Lilly Ges.m.b.H, Vienna, Austria.; Department of Dermatology, Medical University of Vienna, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Foley+P%22">Foley P</searchLink>; Skin Health Institute, Carlton, Australia.; The University of Melbourne, St Vincent's Hospital Melbourne, Fitzroy, Australia. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228918133%22">The Journal of dermatological treatment</searchLink> [J Dermatolog Treat] 2022 Feb; Vol. 33 (1), pp. 329-335. <i>Date of Electronic Publication: </i>2020 Apr 21. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Informa+Healthcare%22">Informa Healthcare </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>8918133 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1471-1753 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209546634%22">09546634 </searchLink><i>NLM ISO Abbreviation: </i>J Dermatolog Treat <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32314628 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/09546634.2020.1752888 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 329 Titles: – TitleFull: A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Spelman L – PersonEntity: Name: NameFull: Rubel D – PersonEntity: Name: NameFull: Brnabic A – PersonEntity: Name: NameFull: Burkhardt N – PersonEntity: Name: NameFull: Riedl E – PersonEntity: Name: NameFull: Foley P IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2022 Feb Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1471-1753 Numbering: – Type: volume Value: 33 – Type: issue Value: 1 Titles: – TitleFull: The Journal of dermatological treatment Type: main |
| ResultId | 1 |
